Gene and Cell Therapy – News and Features

Amorcyte lead product, AMR-001, is an autologous stem cell product for the treatment of damaged heart muscle following AMI.

Oraginization's website provides comprehensive summaries and analysis of over 1200 patents hand-picked by experts in the field to be of relevance to stem cell commercialization and development.

GBI has begun process development and will be manufacturing a monoclonal antibody used by Q Therapeutics in purifying its cell therapy product, Q-Cells™.

Company strengthens scaffold-engineering capabilities with electrospinning platform technology and team.

Neural cells derived from hESC helped repair stroke-related damage in the brains of rats and led to improvements in their physical abilities after a stroke.

Researchers report that the patients with CLL who were treated with a gene therapy protocol began making antibodies that reacted against their own leukemia cells.

RNL Bio has signed an initial 12 month tenancy agreement for a unit at the ‘Cels at Newcastle’ bio-incubator at Newcastle University's Medical School.

JDRF is providing $500,000 over two years of research funding aimed at developing an insulin-producing beta cell therapy product for the treatment of type 1 diabetes.

RNL Bio entered into an agreement with Tiantan Puhua Hospital for stem cell treatments for complications including spinal cord injury, hair loss and osteoarthritis.

Genes have the ability to recognize similarities in each other from a distance, without any proteins or other biological molecules aiding the process, according to new research.